Overview

Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer

Status:
Completed
Trial end date:
2016-08-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look for an improvement in progression free survival with the combination of bevacizumab, carboplatin and pemetrexed in patients with newly diagnosed advanced/metastatic non small cell lung cancer. Overall survival and safety will also be assessed.
Phase:
Phase 2
Details
Lead Sponsor:
Christiana Care Health Services
Collaborator:
Eli Lilly and Company
Treatments:
Bevacizumab
Carboplatin
Pemetrexed